Develops experimental cancer medicines for patients with solid and blood cancers, using its ProTide technology to alter nucleoside-based chemotherapy.
20-F for FY2025, filed Mar 19, 2026We are a clinical-stage biopharmaceutical company focused on significantly improving treatment outcomes for patients with cancer by…View ↗
Loading...